Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus HUMALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus HUMALOG.
ADMELOG SOLOSTAR vs HUMALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipocytes, leading to increased glucose uptake and reduced hepatic glucose production.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 3 or more doses, given within 15 minutes before or immediately after a meal. Typical total daily dose range 0.5-1.0 units/kg/day.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
Subcutaneous: 0.5-1.0 hour (insulin lispro); longer with renal impairment (up to 1.5-3 hours).
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
Renal: 60-80% as unchanged drug; biliary/fecal: minor (<10%).
Category C
Category C
Insulin
Insulin